CRVO_OUT_1 [2025-04-02 10:25:10 -0400] 3131 Bytes | 923 tokens | Cum: 923 tkns (11.54% of 8k)
==========================================================================

Booyah, my friends! It's already 10:25:09 AM on Wed Apr 02, 2025 -0400, and I've got my eyes locked on CervoMed (CRVO), pushing up to 12.3045 from 9.98. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: CervoMed (CRVO)
IPO: 1996-06-18 (28 Years Ago)
Market Cap: $86,853,136
Shares Outstanding: 8,700,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Here's the first list of news for CervoMed:

C1 - Today 07:00AM - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025
C2 - Mar-31-25 02:34PM - Biotech Stocks Q1 2025 Recap: Winners And Underperformers
C3 - Mar-25-25 08:00AM - CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD )
C4 - Mar-22-25 11:00AM - Investors To Focus On PCE Price Index Print As Cintas, Lululemon To Report Earnings
C5 - Mar-22-25 11:00AM 02:55AM - CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
C6 - Mar-19-25 04:27PM - Is CervoMed Inc. (CRVO) Among the Best Short Squeeze Stocks to Buy According to Analysts?
C7 - Mar-18-25 04:48AM - CervoMed Inc. (CRVO): The Best Short-Term Stock to Buy Right Now
C8 - Mar-17-25 08:00AM - CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

Prior AI Reports for CRVO:
1. 2025-03-27 – Score: 50 – Target: 11.2800 – Highs: 10.7200 / 9.6865 / 10.07
high-sales-growth-amid-negative-returns-sparks-uncertainty
2. 2025-03-21 – Score: 85 – Target: 21.6000 – Highs: 16.9400 / 14.9678 / 10.53
cervomed-incs-skyrocketing-sales-signal-bullish-market-trend
3. 2025-03-20 – Score: 65 – Target: 13.2500 – Highs: 12.2700 / 16.9400 / 14.97
cervomeds-strong-growth-tempered-by-market-skepticism

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on CervoMed (CRVO)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

CRVO_OUT_3 [2025-04-02 10:25:16 -0400] 1099 Bytes | 320 tokens | Cum: 1245 tkns (15.56% of 8k)
==========================================================================

Showing C1 (chunk 1 of 13): C1:
**Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD 2025**
Date: Today 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/02/3054108/0/en/Investigators-to-Present-Clinical-Trial-Results-Showing-Neflamapimod-Slows-Clinical-Progression-in-Dementia-with-Lewy-Bodies-in-Oral-Presentation-at-AD-PD-2025.html

April 02, 2025 07:00 ET| Source:CervoMed Inc.CervoMed Inc.

During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC)

Neflamapimod was associated with a reduced incidence of falls in the Extension phase of the study and new data to be presented at AD/PD

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_5 [2025-04-02 10:25:18 -0400] 1025 Bytes | 284 tokens | Cum: 1647 tkns (20.59% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T11:33:26Z - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in D...
A2 - 2025-04-02T11:28:03Z - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in D...
A3 - 2025-04-02T11:19:10Z - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in D...
A4 - 2025-04-02T11:09:45Z - Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in D...
A5 - 2025-04-02T08:06:10Z - CervoMed Inc. (NASDAQ:CRVO) Given Average Recommendation of "Moderate Buy" by Analysts...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

CRVO_OUT_7 [2025-04-02 10:25:23 -0400] 1101 Bytes | 312 tokens | Cum: 1961 tkns (24.51% of 8k)
==========================================================================

Showing A1 (chunk 1 of 16): A1:
**Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025**Date: 2025-04-02Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/02/tmt-newswire/globenewswire/investigators-to-present-clinical-trial-results-showing-neflamapimod-slows-clinical-progression-in-dementia-with-lewy-bodies-in-oral-presentation-at-adpd-2025/2085028Anfield Appoints Ross McElroy to Board of Directors and Announces Results of Special Shareholder Meeting

During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical Global Impression of Change (CGIC)

Neflamapimod was associated with a

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_9 [2025-04-02 10:25:23 -0400] 1026 Bytes | 308 tokens | Cum: 2377 tkns (29.71% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-01-29T13:00:00Z - CervoMed to Present at the 8th International Lewy Body Dementia Conference
B2 - 2024-10-02T12:00:00Z - CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
B3 - 2024-06-11T12:00:00Z - CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
B4 - 2024-04-08T12:00:36Z - Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
B5 - 2024-04-01T12:00:00Z - CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
B6 - 2024-03-28T12:30:00Z - CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_11 [2025-04-02 10:25:27 -0400] 725 Bytes | 213 tokens | Cum: 2592 tkns (32.40% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**CervoMed to Present at the 8th International Lewy Body Dementia Conference**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/29/3017093/0/en/CervoMed-to-Present-at-the-8th-International-Lewy-Body-Dementia-Conference.htmlCervoMed, a clinical-stage company, announced that topline results from its Phase 2b RewinD-LB study of neflamapimod in dementia with Lewy bodies will be presented at the 8th International Lewy Body Dementia Conference in Amsterdam on January 31, 2025.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_13 [2025-04-02 10:25:28 -0400] 1100 Bytes | 308 tokens | Cum: 2966 tkns (37.08% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S2 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

S3 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto ...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

CRVO_OUT_15 [2025-04-02 10:25:33 -0400] 1041 Bytes | 265 tokens | Cum: 3233 tkns (40.41% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition

On March 17, 2025, CervoMed Inc. (the Company, we or us) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2024. A copy of that press release is attached hereto as Exhibit99.1 and incorporated herein by reference.

The information included in or incorporated by reference into this Item 2.02 (including Exhibit99.1) is being furnished pursuant to Item 2.02 of Form 8-K and shall not be deemed to be filed for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act), or the Exchange Act....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

CRVO_OUT_17 [2025-04-02 10:25:41 -0400] 4171 Bytes | 1221 tokens | Cum: 4582 tkns (57.27% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-----------------------+------------------------+
| Volume: 758,837 | Perf Month: 484.67% | Option/Short: No / No | Sales Y/Y TTM: 142.42% |
+-------------------+-----------------------+-----------------------+------------------------+
| Avg Volume: 4.64M | Perf Quarter: 418.62% | Short Float: 46.70% | ROE: -69.95% |
+-------------------+-----------------------+-----------------------+------------------------+
| Rel Volume: 1.11 | Index: RUT | Short Ratio: 0.57 | ROI: -41.56% |
+-------------------+-----------------------+-----------------------+------------------------+
| RSI (14): 68.32 | Market Cap: 107.87M | Short Interest: 2.63M | Sales Surprise: 40.76% |
+-------------------+-----------------------+-----------------------+------------------------+
| ATR (14): 1.84 | Shs Outstand: 8.70M | Beta: -0.26 | EPS Surprise: -24.55% |
+-------------------+-----------------------+-----------------------+------------------------+
| SMA20: 57.17% | Shs Float: 5.64M | Sales Q/Q: -13.19% | P/E: - |
+-------------------+-----------------------+-----------------------+------------------------+
| SMA50: 175.81% | Inst Own: 17.08% | Sales past 5Y: 7.26% | Earnings: Mar 17 BMO |
+-------------------+-----------------------+-----------------------+------------------------+
| SMA200: 20.57% | Insider Own: 35.20% | Employees: 15 | |
+-------------------+-----------------------+-----------------------+------------------------+
| Perf Week: 60.77% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+-------------------+-----------------------+-----------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 9737974.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -16290695.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 12.36
Average Volume: 12132416.74
30-Day High: 14.29
30-Day Low: 2.12

[Detailed Financials: TTM 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: TTM 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $1,206,650.0

[Detailed Financials: FY 2024]
- Total Assets: $43,081,610.0
- Total Liabilities: $3,879,282.0
- Total Equity: $39,202,328.0
- Current Assets: $43,081,610.0
- Current Liabilities: $3,879,282.0

[Income Statement: FY 2024]
- Revenue: $9,737,974.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.02

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $1,206,650.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

CRVO_OUT_19 [2025-04-02 10:25:43 -0400] 676 Bytes | 167 tokens | Cum: 4958 tkns (61.98% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

CRVO_IN_21 [2025-04-02 10:25:43 -0400] 126 Bytes | 29 tokens | Cum: 5015 tkns (62.69% of 8k)
==========================================================================

====================================
[2025-04-02 10:25:43] # Analysis Completed
Elapsed Time: 33.81 seconds